Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Preusser

Showing results (241-250 of 527) with videos related to

Pageof 53
Sort By:
ESMO Open|July 13, 2019
Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussionAnna S Berghoff, Beatriz Bellosillo, Christophe Caux, et al.
Anticancer Research|July 31, 2013
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tractAysegül Ilhan-Mutlu, Matthias Preusser, Sebastian F Schoppmann, et al.
Trends in Cancer|March 7, 2018
The Evolving Landscape of Brain MetastasisManuel Valiente, Manmeet S Ahluwalia, Adrienne Boire, et al.
ESMO Open|November 16, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Günther G Steger, et al.
Oncology|November 28, 2014
Thalidomide as palliative treatment in patients with advanced secondary glioblastomaMarco Ronald Hassler, Cornelia Sax, Birgit Flechl, et al.
Neuro-Oncology Advances|December 31, 2024
Evaluation of early metabolic changes following vorasidenib using FET PET in patients with <i>IDH</i>-mutant gliomasNorbert Galldiks, Jan-Michael Werner, Isabelle Stetter, et al.
Cancer Immunology, Immunotherapy : CII|May 6, 2021
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent gliomaMaximilian J Mair, Ayseguel Ilhan-Mutlu, Sahra Pajenda, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2020
Venous thromboembolic events in patients with brain metastases: the PICOS scoreFabian Wolpert, Anna S Berghoff, Bettina Grossenbacher, et al.
Pathology Oncology Research : POR|May 7, 2020
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control StudyAndrea Beer, Hossein Taghizadeh, Ana-Iris Schiefer, et al.
Cancer Treatment Reviews|April 19, 2021
Neurological complications of cancer immunotherapyPatrick Roth, Sebastian Winklhofer, Antonia M S Müller, et al.
Pageof 53

Showing results (241-250 of 527) with videos related to

Sort By:
Pageof 53
ESMO Open|July 13, 2019
Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussionAnna S Berghoff, Beatriz Bellosillo, Christophe Caux, et al.
Anticancer Research|July 31, 2013
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tractAysegül Ilhan-Mutlu, Matthias Preusser, Sebastian F Schoppmann, et al.
Trends in Cancer|March 7, 2018
The Evolving Landscape of Brain MetastasisManuel Valiente, Manmeet S Ahluwalia, Adrienne Boire, et al.
ESMO Open|November 16, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Günther G Steger, et al.
Oncology|November 28, 2014
Thalidomide as palliative treatment in patients with advanced secondary glioblastomaMarco Ronald Hassler, Cornelia Sax, Birgit Flechl, et al.
Neuro-Oncology Advances|December 31, 2024
Evaluation of early metabolic changes following vorasidenib using FET PET in patients with <i>IDH</i>-mutant gliomasNorbert Galldiks, Jan-Michael Werner, Isabelle Stetter, et al.
Cancer Immunology, Immunotherapy : CII|May 6, 2021
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent gliomaMaximilian J Mair, Ayseguel Ilhan-Mutlu, Sahra Pajenda, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2020
Venous thromboembolic events in patients with brain metastases: the PICOS scoreFabian Wolpert, Anna S Berghoff, Bettina Grossenbacher, et al.
Pathology Oncology Research : POR|May 7, 2020
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control StudyAndrea Beer, Hossein Taghizadeh, Ana-Iris Schiefer, et al.
Cancer Treatment Reviews|April 19, 2021
Neurological complications of cancer immunotherapyPatrick Roth, Sebastian Winklhofer, Antonia M S Müller, et al.
Pageof 53